Synektik_presentation_Q1_2023 r._final_EN.pptx

SYNEKTIK SA Synektik SA | Investor Presentation Q1 2023 FY

1. Q1 2023 PERFORMANCE INVESTOR PRESENTATION February 2024

2. COMPANY PROFILE Integrator of innovative solutions for medicine Largest manufacturer and supplier of radiopharmaceuticals in Poland Research and Development Centre focused on developing innovative particles and radiopharmaceutical products Developer of special medical software and applications Leading supplier of advanced medical technologies Provider of maintenance and measurement services SELECTED FINANCIAL DATA SELECTED MARKET INFORMATIO N Market capitalisation and ratios calculated using the 1 4 February 202 4 Enterprise value = market capitalisation as of 1 4 February 202 4 + net debt as of 3 1 December 2023 Net profit adjusted for one-off items EBITDA from recurring operations, adjusted for one-off items 1.10.2023-31.12.2023 1.10.2022-30.09.2023 Indexes WIG, sWIG80, WIGTECH, WIG-Poland ISIN PLSNKTK0001 Number of shares 8 529 129 Capitalisation (1) PLN 930m Enterprise value (2) PLN 771m P/E (3) 10.8 EV/EBITDA (4) 6.4 Consolidated data in PLNm Q1 2023 (6) FY 2022 (7) Revenue from sales 271.3 446.9 Recurring EBITDA (4) 53.1 97.3 Net profit 34.7 52.5 Recurring net profit (3) 38.9 69.3 Equity 168.9 134.2 Net debt (158.9) (43.9) ABOUT SYNEKTIK GROUP

3. Sales of equipment and IT solutions – growing revenues and profits Radiopharmaceuticals – growth in revenues and profitability PLN 9.9 million in revenue (excluding intra-group transactions), up 30% y/y Increase in sales of essential radiopharmaceuticals by 62%, to PLN 5.7 million Increase in EBITDA by 182% y/y, to PLN 4.2 million Increase in revenue from sales of medical equipment by 91%, to PLN 219.2 million, generated in part through the fulfillment of 12 orders for the delivery of da Vinci robots, a ZAP-X system and a set of equipment for diagnostic imaging Increase in recurring revenue by 97%, to PLN 42.2 million EBITDA of PLN 53.1 million Research and development – selection of a proprietary molecule Preparations to launch clinical trials in the United States, technology transfer in progress Decision to continue the project based solely on the molecule in respect of which 100% of intellectual property rights and patent protection belong to the Synektik Group Patent protection obtained in Japan HIGHLIGHTS OF Q1 FY2023

4. 92% increase in total revenue from sales of equipment, IT solutions and the provision of services, to PLN 261.4 million 30% increase in revenue of the radiopharmaceuticals segment, excluding intra-group transactions, to PLN 9.9 million FINANCIAL PERFORMANCE IN Q1 FY2023 79% increase in recurring net result Consolidated revenue (PLN million) Recurring net result (PLN million) 75% increase in EBITDA of the equipment, IT and services segment, to PLN 53.1 million 182% increase in EBITDA of the radiopharmaceuticals segment, to PLN 4.1 million Recurring EBITDA (PLN million) +89% +78% +79%

5. CHANGE IN RECURRING EBITDA W mln PLN Q1 2022 FY Q1 2023 FY +23.37

6. 53.1 Summary EBITDA growth driven by: considerable increase in sales of equipment used in therapy growing scale of recurring sales in both segments acquisition of surgical robotics business in Czech Republic and Slovakia raising margins of radiopharmaceutical business GROUP’S RECURRING EBITDA IN FINANCIAL YEARS 2020-2023 +75% CAGR

7. MEDICAL EQUIPMENT AND IT SOLUTIONS

8. Medical equipment and IT solutions KEY INFORMATION Synektik is a leading supplier of medical equipment and IT solutions used in radiology, oncology, cardiology and neurology Main business areas: sales of medical equipment used in radiology, therapy and nuclear medicine, provided by more than a dozen leading manufacturers turnkey preparation and fit-out of operating rooms and diagnostic centers/radiology facilities in-house IT solutions for archiving, distribution, presentation and processing of radiological images and administrative data, along with diagnostic and review stations medical equipment repair, maintenance and calibration services Zbadani.pl innovative teleradiology platform project

9. Medical equipment and IT solutions Rapid growth in revenues and profits SUMMARY 92% y/y increase in revenue s in Q1 FY2023, to PLN 261.4 million 75% y/y increase in recurring EBITDA in Q1 FY2023, to PLN 53.1 million PLN 172.5 million revenue from sales of medical equipment in Q1 FY2023 (PLN 90.8 million the year before) 97% increase in recurring revenue from sales of services (repair and maintenance, warranty, IT) and supplies of consumable instruments and accessories in Q1 FY2023, to PLN 42.2 million

10. Medical equipment and IT solutions Promising prospects for FY2023 SUMMARY Acquisition of orders worth PLN 172.5 million in Q1 FY2023 (PLN 90.8 million the year before), including, without limitation, for the delivery of: ZAP-X system 13 da Vinci systems set of equipment for diagnostic imaging Total value of the backlog and active bids at the end of Q1 FY2023: PLN 127.7 million compared to PLN 132.2 million as at 31 December 2022

11. Over 2,100 da Vinci assisted procedures in Q1 FY2023 (up 95% y/y), 7,000 in the last 4 quarters (up +100% y/y) Installation in Q1 FY2023 of 8 da Vinci systems for Polish customers (6 new systems, 2 buyouts of leased equipment) Contract with the Maria Sklodowska-Curie Bialystok Oncology Center (worth PLN 13.3 million) for the delivery of a da Vinci system in FY2023 Market growth outlook according to a PMR report ( Surgical robotics market in Poland 2023 ): 80+ new robotic installations over the next 5 years, 43,000 assisted procedures in 2028 Medical equipment and IT solutions da Vinci in Poland – SUMMARY AND OUTLOOK

12. Nearly 2,100 da Vinci assisted procedures in Q1 FY2023 (up 42% y/y), 7,500 in the last 4 quarters (up +32% y/y) Installation in Q1 FY2023 of 4 da Vinci systems for Czech customers (including one system replacement) Contract with St. Anne’s University Hospital Brno worth CZK 89.4 million for the delivery of a da Vinci system in FY2023 Execution of a contract with the Thomayer University Hospital in Prague for the supply of consumables worth USD 3.0 million Medical equipment and IT solutions da Vinci in the Czech Republic and Slovakia – SUMMARY AND OUTLOOK

13. 24 3 kw. 2023 r. 23 2 kw. 2023 r. 19 4 kw. 2022 r. 16 3 kw. 2022 r. 15 2 kw. 2022 r. 16 1 kw. 2022 r. 33 3 kw. 2023 r. 31 2 kw. 2023 r. 22 4 kw. 2022 r. 20 3 kw. 2022 r. 17 2 kw. 2022 r. 17 1 kw. 2022 r. 16 4 kw. 2021 r. 15 3 kw. 2021 r. 14 2 kw. 2021 r. 14 1 kw. 2021 r. 13 4 kw. 2020 r. 12 3 kw. 2020 r. 10 2 kw. 2020 r. 9 1 kw. 2020 r. 8 4 kw. 2019 r. 6 3 kw. 2019 r. 6 2 kw. 2019 r. 6 1 kw. 2019 r. 4 4 kw. 2018 r. 1 3 kw. 2018 r. DA VINCI Systems IN POLAND* DA VINCI Systems IN czech Republic and slovakia * *Being serviced by Synektik, including systems leased from Synektik Warszawa Wrocław Białystok Poznań Kraków Siedlce Wieliszew Szczecin Gdańsk Gorzów Wlkp. Lublin Gdynia Katowice Bydgoszcz Rzeszów Łódź Toruń Usti nad Labem Pilzno Ceske Budejovice Hradec Kralove Velke Meziricí Brno Novy Jicin Ołomuniec Banska Bystrica Ostrava Praga Martin Jihlawa Liberec Bratysława MEDICAL EQUIPMENT AND IT SOLUTIONS DA VINCI SERVICED BY SYNEKTIK Koszyce Kielce Leszno Zlin Częstochowa Słupsk Zielona Góra Olsztyn Pardubice 29 q4 2023 40 Q4 2023

14. RADIOPHARMACEUTICALS

15. Synektik - owned Public Other privately held Radiopharmaceuticals PRODUCTION Synektik is the largest producer and supplier of PET/CT radiopharmaceuticals in Poland Major producer of special radiopharmaceuticals Location of cyclotrons for the production of radiopharmaceuticals used in PET studies Source: Own compilation based on data from the Supreme Audit Office, https://www.nik.gov.pl/aktualnosci/niecertyfikowane-radiofarmaceutyki.html (30.11.2021) Production sites together with R&D Centre 50+ Number of employees 3 Synektik Group products by di agnostic application Wide spectrum of tumours Prostate tumours Bladder tumours Parkinson's disease , neuroendocrine tumours Brain and extracranial tumours Breast and reproductive organ tumours Bone tumours Cholina FDG FLT PSMA Cholina FES FET DOPA Metaflu Axumin

16. RADIOPHARMACEUTICALS RAPID GROWTH IN SALES AND EBITDA SUMMARY 30% y/y increase in sales in Q1 FY2023, to PLN 9.9 million 62% increase in sales of basic tracers, to PLN 5.7 million, as a result of an increase in the number of examinations and changes in selling prices 18% increase in sales of specialty tracers, to PLN 2.2 million 182% increase in EBITDA, to PLN 4.1 million Increase in the segment’s EBITDA profitability from 19% in Q1 FY2022 to 42% in Q1 FY2023)

17. cardiac tracer HIGHLIGHTS Preparations to launch clinical trials in the United States, technology transfer in progress Decision to continue the project based solely on the molecule in respect of which 100% of intellectual property rights and patent protection belong to the Synektik Group. Signing of an agreement with Hadasit to terminate cooperation Patent protection obtained in Japan COMPETITIVE ADVANTAGES: Improved image resolution and contrast Reduced radiation dose Quantitative analysis of myocardial blood supply in absolute values Ability to image challenging patients Shorter radiation retention time [1] DISCOVERY [2] PRECLINICAL PHASE [3] CLINICAL TRIALS [4] APPROVAL BY THE FDA AND THE EMA PHASE I PHASE II PHASE III IN VIVO AND IN VITRO RESEARCH SAFETY OF USE, DOSIMETRY EFFECTIVENESS COMPARISON INVESTMENT COST RISK CARDIAC PET TRACER Lead structure discovery, synthesis, evaluation THIS IS WHERE WE ARE

18. WYNIKI FINANSOWE

19. SUMMARY Surplus of cash over financial liabilities of PLN 158.8 million on 30 December 2023 Increase in trade payables related to the completion of large-value orders in the equipment supply segment at the turn of the quarters (settled in the current financial quarter) PLN 122 million in positive operating cash flow in Q1 FY2023 PLN 111 million in positive total cash flows Q1 FY2023 – selected data PLN 000s Q1 FY2023 Q1 FY2022 Sales revenue 271,296 143,814 EBIT 45,367 24,628 Recurring EBITDA 53,145 29,776 Net profit 34,669 19,084 PLN 000s 31 Dec 2023 30 Sep 2023 Non-current assets, including: 138,259 131,291 Property, plant and equipment 45,809 37,663 Other intangible assets 47,553 50,345 Current assets, including: 259,311 168,624 Inventories 17,636 21,273 Trade receivables 62,595 79,659 Cash 173,895 62,663 Equity 168,877 134,201 Non-current liabilities 38,902 47,481 Liabilities under bank loans and borrowings - - Lease liabilities 10,883 13,848 Trade and other liabilities 4,140 11,580 Current liabilities, including: 189,791 118,233 Liabilities under bank loans and borrowings 650 1,300 Lease liabilities 3,388 3,573 Trade and other liabilities 145,794 90,819 Net debt (158,804) (43,942)

20. Dariusz Korecki Vice-President of the Management Board, CFO [email protected] www.synektik.pl THANK YOU